News | May 28, 2009

Study Will Evaluate DEFINITY in Patients With Suboptimal Echocardiograms

May 28, 2009 – Lantheus Medical Imaging Inc. today said it completed patient enrollment of CaRES (Contrast Echocardiography REgistry for Safety Surveillance), the first, multicenter phase IV observational registry that evaluates the use of ultrasound imaging agents in routine clinical practice.

The 1,060 patients who were enrolled at 15 sites in the U.S. were age 18 or older and required DEFINITY Vial for (Perflutren Lipid Microsphere) injectable suspension-enhanced echocardiography because of a previous suboptimal, unenhanced echocardiogram.

The company said the study will provide important clinical information about the use of DEFINITY in a range of patient types and clinical settings. The CaRES registry was established following discussions with the FDA to further explore the clinical use of DEFINITY. The prospective, open-label, nonrandomized, surveillance registry will gather and analyze data on patient demographics and characteristics, reasons for using DEFINITY, results of safety monitoring, and the nature and frequency of any adverse events.

Since DEFINITY received approval for use in the U.S., approximately 2 million doses have been administered to patients with suboptimal echocardiograms to see the borders of the heart more clearly.

Up to 20 percent of resting echocardiography studies will result in suboptimal echocardiograms, Lantheus said. A suboptimal image is one in which at least two out of six myocardial segments of the left ventricle cannot be visualized appropriately, as defined by the American Society of Echocardiography (ASE). The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound| October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
Videos | Cardiovascular Ultrasound| October 12, 2017
Sharon Mulvagh, M.D., FRCPC, FACC, FAHA, FASE, professor, Division of Cardiology, Department of Medicine, Dalhouse Un
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Overlay Init